Research and projectsGrant projects

Grant projects Monitoring the occurrence of alpha-1 antitrypsin deficiency in patients with a severe form of COPD

Coordinator Coordinator: Hejduk Karel

Duration Duration: 2014–2014

Development of a methodically correct way of multicentre monitoring and recording of A1AT deficit examination results in a group of patients who met the criteria of a severe form of COPD.

De-identified data were collected into the registry Czech Multicentre Research Database of COPD, which had been previously developed in cooperation with the Czech Pneumological and Phthisiological Society, and which aims to monitor real mortality and morbidity rates in an unselected group of COPD patients, their declination of lung function and other parameters, including assessment of the patients’ condition over time. A module called “Alpha-1 antitrypsin” was implemented into the structure of this pre-existing project; the parametric structure of this module corresponds to a consensus made by the expert society.

A total number of 452 patients complying with inclusion and exclusion criteria (as specified below) were recruited. Information on the examination of A1AT level was obtained in 402 patients. Further examination was performed in 250 patients, i.e. in 55.3% of the entire group of monitored patients.

Inclusion criteria:

  • Post BDT FEV1 was lower than or equal to 60%
  • Confirmed COPD diagnosis
  • Stable patients’ condition, i.e. at least eight weeks without exacerbation
  • Patients’ residence in the centre’s catchment area (corresponding district)
  • Patients’ consent

Exclusion criteria:

  • Bronchial asthma without COPD
  • Bronchiectasis without CHOPN
  • Cystic fibrosis
  • Terminal stage of a malignancy (death expected within 3 months)
  • End-stage COPD (death expected within 3 months)
  • Significant non-compliance of the patient
  • Significant movement disorder

Two project objectives were defined and successfully accomplished:

  • The first objective was to facilitate the monitoring of patients with alpha-1 antitrypsin deficiency in a group of persons with a severe form of COPD. This objective was met by developing a module called “Alpha-1 antitrypsin” in the structure of a validated database of patients with severe COPD. This module is fully sustainable for years to come. Ensuring a long-term sustainability was also planned as part of the project.
  • The second objective was to perform an analytical evaluation of treatment effectiveness and of pulmonary function, including other indicators of the patients’ condition. This objective was partially met by performing a descriptive analysis. We aim to develop and deepen our knowledge on the issue of alpha-1 antitrypsin deficiency. More detailed analyses will be performed and their results will be published.

Other important information:

  • Funding: The project has been supported by the Ministry of Health of the Czech Republic within the programme “National Health Programme – Health Support Projects”. The project is registered with the identifier 15/14/NAP.
CHOPN registry: epidemiological database of COPD patients in the Czech Republic